Tetrahydro-4H-pyran-4-one: Synthesis and Potential Pharmaceutical Applications
Tetrahydro-4H-pyran-4-one is synthesized using various reagents and solvents, and has pharmaceutical applications as an SSAO inhibitor and a modulator of NMDA receptors.
Jan 9，2024 API
Acyclovir: Antiviral Medication for Herpes with Promising Pharmacokinetics and Potency
Acyclovir treats viral infections. Oral absorption is limited with peak plasma concentrations of 0.5 μg/ml. Dosages vary by indication.
Jan 9，2024 API
Cinnamic Acid: Dietary Sources, Mechanisms of Action and New Formulation
Cinnamic acid in plant-based foods stimulates insulin secretion, but its limited bioavailability led to new formulations like nanoparticles for improved effectiveness against chronic diseases.
Jan 9，2024 API
Understanding the Mechanism, Pharmacokinetics, and Side Effects of Prednisolone
Prednisolone binds to glucocorticoid receptors, with 70% bioavailability. Metabolism involves prednisone conversion. Overdose causes side effects.
Jan 9，2024 API
Zinc Pyrithione: A Promising Anti-Fungal Compound for Dermatologic Applications
Zinc Pyrithione has high skin permeability and exhibits anti-fungal activity against Malassezia yeast, commonly used in medicated shampoos for treating dandruff and seborrheic dermatitis.
Jan 9，2024 API
How is Ibrexafungerp synthesised?
Ibrexafungerp is synthesised in two steps by chemical reaction using enfumafungin as a raw material.
Jan 9，2024 Drugs
Agar-based edible films for food packaging applications
Agar can create edible films with gelling ability. Adding components like plasticizers and biopolymers improves flexibility and functional properties, expanding applications.
Jan 9，2024 API
A first-in-class potent 5-HT2A antagonist: Lumateperone
Lumateperone, also known as ITI-007, is a first-in-class potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transport developed by Intra-Cellular Therapies under a licens
Jan 8，2024 API
The synthesis method of Lemborexant
Lemborexant is an orally administered dual orexin receptor (OXR) antagonist developed by Eisai for the treatment of adults with insomnia.
Jan 8，2024 API
How Lasmiditan works in treating migraine
Lasmiditan, or COL-144, is an orally bioavailable selective serotonin receptor agonist (SSRA) discovered by Eli Lilly and Company and licensed to CoLucid Pharmaceuticals before Eli Lilly acquired CoLu
Jan 8，2024 API